Method of treating arrhythmias

• US 6,537,974 B2
• Filed: 09/07/2001
• Issued: 03/25/2003
• Est. Priority Date: 09/08/2000
• Status: Expired due to Fees

• Current Assignee: CV Therapeutics Inc (Gilead Sciences Inc.)
• Original Assignee: CV Therapeutics Inc (Gilead Sciences Inc.)
• Inventors: Wolff, Andrew
• Primary Examiner(s): Wilson, James O.
• Assistant Examiner(s): MCINTOSH III, TRAVISS C
• Application Number:
  US09/949,169
• Publication Number:
  US 20020055485A1
• Time in Patent Office: 564 Days
• Field of Search: 514/46, 514/261, 514/263, 514/264, 514/266, 544/262, 544/264
• US Class Current: 514/46
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61P 9/06 Antiarrhythmics

Abstract

A method for treating arrhythmia in mammals is provided comprising administering a low dose of an adenosine receptor agonist of the Formula I:

wherein R₁ is an optionally substituted heterocyclic group, preferably monocyclic.

Claims

1. A method for treating arrhythmia in a mammal, comprising administering to a mammal in need of such treatment, a therapeutically effective dose in the range of 0.0003-0.009 mg/kg of an adenosine A₁ receptor agonist of Formula I:

wherein R₁ is an optionally substituted heterocyclic group.

2. The method of claim 1, wherein R₁ is 3-tetrahydrofuranyl, 3-tetrahydrothiofuranyl, 4-pyranyl, or 4-thiopyranyl.

3. The method of claim 2, wherein R₁ is 3-tetrahydrofuranyl.

4. The method of claim 3, wherein R₁ is (R)-3-tetrahydrofuranyl, namely 6-(3-(R)-aminotetrahydrofuranyl)purine riboside.

5. The method of claim 4, wherein the administration is by intravenous injection.

6. The method of claim 4, wherein administration is by a single bolus.

7. The method of claim 1 where the arrhythmias are selected from the group consisting of atrial fibrillation, atrial flutter, and paroxysmal atrial tachycardia.

8. The method of claim 7, wherein R₁ is 3-tetrahydrofuranyl, 3-tetrahydrothiofuranyl, 4-pyranyl, or 4-thiopyranyl.

9. The method of claim 8, wherein R₁ is 3-tetrahydrofuranyl.

10. The method of claim 9, wherein R₁ is (R)-3-tetrahydrofuranyl, namely 6-(3-(R)-aminotetrahydrofuranyl)purine riboside.

11. The method of claim 1 wherein said mammal is a human.